(Wired) – House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer genetic data under a change of ownership.

Signed by 20 other Democratic members of Congress, the letters—which can be read here and here—were sent to Regeneron Pharmaceuticals and TTAM Research Institute, which have put forth separate bids to buy 23andMe. In the letters, they ask Regeneron and TTAM if they will continue to give customers the option to delete their data and withdraw consent for their data to be used in medical research. They also want to know if 23andMe’s current policy of not sharing genetic data with law enforcement without a warrant will be upheld, and whether both entities intend to proactively notify 23andMe customers about the sale. (Read More)